Find out about different medications that can help manage your symptoms of ADPKD (autosomal dominant polycystic kidney disease), slow its progression and reduce your risk of complications.
Medications to treat the symptoms of ADPKD
If you have autosomal dominant polycystic kidney disease (ADPKD), your kidney specialist or other doctor may recommend medication to help manage your symptoms and reduce the chance of future complications (knock-on effects such as high blood pressure).
Medications for ADPKD symptoms include:
- Blood pressure tablets to stop your blood pressure becoming too high
- Antibiotics to treat infections of the urinary tract, kidney or liver cysts
- Pain relief, to treat short- or long-term pain
Whether you need any of these medications will depend on the symptoms you have, and could change over time. Your kidney specialist or other doctor will be able to explain which treatments might be right for you, and why.
Click on the links above to find out more about particular symptoms and the medications that can help.
Medication to slow the progress of ADPKD: tolvaptan
If you have ADPKD, your condition is likely to get worse over time. This is called progression. The speed at which your ADPKD will progress is influenced by the faulty gene that caused your ADPKD and sometimes your family history too. ADPKD can progress at different rates in different people.
A new treatment has been approved in Europe for adults that can help slow the progression of ADPKD: tolvaptan (Jinarc®). Tolvaptan is taken orally (as a tablet). It can slow the rate at which your kidneys become enlarged by cysts and can help to slow the speed at which your kidney function declines. Tolvaptan does not alter the growth of liver cysts.
Tolvaptan is not available for all patients with ADPKD. The organisations that recommend which medicines the NHS uses (the National Institute for Health and Care Excellence [NICE] in England and Wales, and Scottish Medicines Consortium [SMC] in Scotland), have set the following guidance based on the stage of a person’s kidney disease:
- In England and Wales, tolvaptan can be prescribed to adults with ADPKD, chronic kidney disease (CKD) stage 2 or 3, and evidence that the disease is progressing rapidly
- In Scotland, tolvaptan can be prescribed to adults with ADPKD, CKD stage 1, 2 or 3, and evidence that the disease is progressing rapidly
Your kidney specialist can tell you whether tolvaptan is suitable for you, and explain the benefits and risks.
The UK Kidney Association has published guidance to help doctors identify patients who may be suitable for tolvaptan.
If you are unsure of the stage of your kidney disease, the below table may help, or your kidney specialist or doctor can confirm this for you.
Kidney disease stages
|eGFR in ml/min/1.73 m2
Normal (although some signs of kidney damage)
90 or more
60 to 89
30 to 59
15 to 29
Very severely reduced = kidney failure
Less than 15 (or having dialysis)
Q&A on tolvaptan
The NICE and SMC guidance on tolvaptan says that patients should have ‘evidence of rapidly progressing disease’ to be considered for tolvaptan treatment. So, what does this mean? UK kidney experts have developed a guide for kidney specialists to help them judge whether a person’s ADPKD is progressing quickly. The guidance is very detailed, but in essence they say that you may have rapidly progressing disease if you meet one of the following criteria:
- The amount of waste that your kidneys can filter from your blood is notably decreasing each year. This is calculated from blood tests that measure your eGFR
- Scans show that your kidneys have increased in size over the last 6 to 12 months
- Your medical history shows there’s a high risk your ADPKD will progress quickly (for example, this could be based on your scan results, the particular genes causing your ADPKD, or your family history)
You may want to ask your kidney specialist how quickly they think your ADPKD will progress, and to explain what they are basing this on. Your kidney specialist or other doctor may not be able to tell you this immediately, because they may require the results of further investigations (blood or imaging tests).
Yes. If you’re already taking tolvaptan, your kidney specialist or other doctor can continue to prescribe it to you until you decide together that it’s the right time to stop.
Tolvaptan works by blocking a hormone called vasopressin in your body. Vasopressin has a few roles in your body, including controlling the amount of water you retain. By counteracting vasopressin, tolvaptan can reduce the levels of a natural chemical, cyclic AMP, in the kidney that encourages cysts to grow. This can help to slow the speed at which your kidney function declines.
A clinical trial (TEMPO 3/4) tested how well tolvaptan works compared with placebo (a ‘dummy’ pill) for patients with rapidly progressing ADPKD. After 3 years, patients taking tolvaptan had kidneys that had enlarged at half the rate of those taking placebo. Tolvaptan also reduced the rate at which patients’ kidney function got worse. This is very promising and is the first treatment to directly tackle ADPKD and provide a direct benefit to patients with ADPKD.
The side-effects of tolvaptan include:
- Being thirsty and having to drink more water
- Passing more urine in the day and night
- Changes in liver function tests: less than 1 in 100 patients in trials showed severe changes in the blood tests for liver function. These changes reversed on stopping tolvaptan, but if they had gone unnoticed, they might have caused serious liver problems. As a result, ALL patients being treated with tolvaptan will need regular monitoring of their liver function (i.e. tests at least once a month).
For many people, the benefits of tolvaptan will outweigh the disadvantages. But in the main clinical trial, about 23 in every 100 patients stopped taking tolvaptan because of the side-effects.
If you’re taking tolvaptan, you’ll have regular monitoring to check your liver health.
Tolvaptan is not recommended if you have stage 4 or 5 kidney disease. If you have stage 4 or 5 kidney disease, your kidneys have already been damaged. You won’t benefit from tolvaptan, as it cannot reverse damage already done.
NICE in England and the SMC in Scotland use slightly different criteria to make recommendations about medicine prescriptions, so sometimes their advice can differ. The NICE experts who reviewed tolvaptan did not believe there was enough proof that patients with stage 1 disease benefited from tolvaptan to justify the cost of treatment. To make things clearer and to give extra advice to doctors, the Renal Association Working Group on Tolvaptan has developed additional guidance.